Cogent Biosciences
US-based Cogent Biosciences develops biotech solutions for genetically driven diseases.
Founded
2014US-based Cogent Biosciences develops biotech solutions for genetically driven diseases.
Founded in Waltham, United States, Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically driven diseases. The core mission of the company is to design rational, biology-validated treatments that address the underlying causes of these conditions, thereby offering real hope to patients. Cogent Biosciences focuses on leveraging advanced scientific research to create effective solutions for millions of people worldwide who are affected by genetically defined diseases.
Cogent Biosciences has garnered attention for its innovative approach and significant potential impact in the biotech industry. The company has attracted notable investors and partnerships, which have been crucial in advancing its research and development efforts. Key achievements include the development of promising therapeutic candidates that are currently undergoing clinical trials. Overall, Cogent Biosciences is making a substantial impact by pushing the boundaries of precision medicine and offering new possibilities for patients with genetically driven diseases.
Companies similar to Cogent Biosciences include BridgeBio Pharma, Encoded Therapeutics, Triplet Therapeutics and Praxis Precision Medicines.
Cogent Biosciences was founded in 2014.
Cogent Biosciences' headquarters is located in Waltham, MA, US.
Cogent Biosciences' most recent funding round was for $150M (USD) in June 2023.
As of Jun 6, 2023, Cogent Biosciences has raised a total of $692.7M (USD).
Cogent Biosciences has 138 employees as of Feb 6, 2024.
Triplet Therapeutics
triplettx.com
